Home Stock

Stock Research: Bio-Rad Laboratories

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Bio-Rad Laboratories

NYQ:BIO US0905722072
67
  • Value
    30
  • Growth
    51
  • Safety
    Safety
    96
  • Combined
    62
  • Sentiment
    49
  • 360° View
    360° View
    67
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bio-Rad Laboratories develops, manufactures, and markets products for life science research and clinical diagnostics. It operates in the Life Science and Clinical Diagnostics industries. Its products are sold globally to hospital laboratories, diagnostic reference laboratories, and physician office laboratories. In the last fiscal year, the company had a market cap of $6784 million, profits of $1379 million, and revenue of $2567 million, with 7700 employees.

more

ANALYSIS: With an Obermatt 360° View of 67 (better than 67% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bio-Rad Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Bio-Rad Laboratories. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 51% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 96 which means that the company has a financing structure that is safer than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 30 which means that the share price of Bio-Rad Laboratories is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 70% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Safety
Country USA
Industry Life Sciences Tools & Services
Size Large
Website bio-rad.com
Index
D.J. US Health Care
S&P MIDCAP
Bio-Rad Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
30 61 60 49
Growth
51 3 9 17
Safety
Safety
96 97 86 96
Sentiment
49 13 36 61
360° View
360° View
67 25 45 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
5 40 69 88
Opinions Change
50 8 50 50
Pro Holdings
n/a 31 24 65
Market Pulse
68 40 43 16
Sentiment
49 13 36 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
30 61 60 49
Growth
51 3 9 17
Safety Safety
96 97 86 96
Combined
62 64 50 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
56 64 57 50
Price vs. Earnings (P/E)
15 32 47 10
Price vs. Book (P/B)
74 84 85 100
Dividend Yield
1 1 1 1
Value
30 61 60 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
28 12 20 7
Profit Growth
64 26 34 68
Capital Growth
51 11 29 27
Stock Returns
60 51 27 55
Growth
51 3 9 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
69 60 62 82
Refinancing
85 70 63 49
Liquidity
82 64 63 81
Safety Safety
96 97 86 96

Similar Stocks

Discover high‑ranked alternatives to Bio-Rad Laboratories and broaden your portfolio horizons.

Oracle

NYQ:ORCL
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews